« Return to News | CROs/Service Providers

Crystal3 Labs acquired by Vithalbhai Dhaduk

Monday, December 19, 2011 10:42 AM

Crystal3 Labs, a cGMP contract research organization based in Boca
Raton, FL, has been acquired by an individual investor, Vithalbhai Dhaduk, M.D., of Fargo, ND. Financial terms of the transaction were not disclosed. The company will also change its name to Global Pharma Analytics.

Founded in 2007, Global Pharma Analytics provides pharmaceutical research
services and analytical testing of drugs and medical devices for the pharmaceutical and biotechnology industries. The company employs 6 people
in Florida.

Dr. Dhaduk serves as chairman of several biotech companies he cofounded. He is also an actively practicing neurologist and is currently chief of neurology at the Community Medical Center in Scranton, PA.

"Our name change reflects our increased investment in developing CRO services to meet the needs of pharmaceutical and biotechnology companies conducting research around the world. We look forward to working closely with Dr. Dhaduk, as his wisdom and extensive industry experience will be very valuable to us and to our clients,"  said Satish Chandran, Ph.D., chief executive officer at Global Pharma.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.